Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancer

Journal of Clinical Pharmacology

Volumn 53, Issue 9, 2013, Pages 946-954

  Cox, Donna S ^a   Papadopoulos, Kyri ^b   Fang, Lei ^a   Bauman, John ^a   Lorusso, Patricia ^c   Tolcher, Anthony ^b   Patnaik, Amita ^b   Pendry, Carolyn ^a   Orford, Keith ^a   Ouellet, Daniele ^a  

^a GLAXOSMITHKLINE   (United States)

^b South Texas Accelerated Research Therapeutics   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Bioavailability; Food effect; Long half life; MEK inhibitor; Pharmacokinetics; Trametinib

Indexed keywords

FENTANYL; TRAMETINIB;

ACNE; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DERMATITIS; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC ENCEPHALOPATHY; MUCOSA INFLAMMATION; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

BIOAVAILABILITY; FOOD-EFFECT; LONG HALF-LIFE; MEK INHIBITOR; PHARMACOKINETICS; TRAMETINIB;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; DIET, HIGH-FAT; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES;

EID: 84885070812     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.115     Document Type: Article

References (16)

1. Nissan MH, Solit DB. The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? Curr Oncol Rep. 2011;13(6):479-487.
2. McCubrey JA, Stellman LS, Chappell WH, et al. Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta. 2007;1773:1263-1284. (Pubitemid 47125967)
3. Pratilas CA, Taylor BS, Ye Q, et al. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling, elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106(11):4519-4524.
4. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPKRAS- RAF signaling pathway in cancer therapy. Exp Opin. 2012;16 (1):103-119.
5. Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of UTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011;39:23-31.
6. Jing J, Greshock J, Holdbrook JD, et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther. 2011;11(3):720-729.
7. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
8. Abe H, Kikuchi S, Hayakawa K, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med Chem Lett. 2011;2:320-324.
9. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol. 2012;13 (8):773-781.
10. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782- 789.
11. Flaherty KT, Robert C, Hersey P, et al. Improved Survival withMEK Inhibition in BRAF-mutated Melanoma. N Engl J Med. 2012;367:107-114.
12. Sausville EA. Promises from Trametinib in RAF active tumors. N Engl J Med. 2012;367:171-172.
13. Guidance for Industry: Bioavailability and Bioequivalence studies for Orally Administered Drug Products-General Considerations, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), December 2002.
14. Almeida S, Spinola AC, Filipe A, Trabelse F, Farre A. Truncated AUCs in the assessment of the bioequivalence of topiramate, a long half-life drug. Arzneimittelforschung. 2007;57(5):249- 253. (Pubitemid 46883226)
15. Sharma A, Slugg PH, Hammett JL, Jusko W. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res. 1998;15:1782-1786. (Pubitemid 28524592)
16. Rowland M, Tozer T. Clinical Pharmacokinetics Concepts and Applications. 2nd ed. Philadelphia, PA, USA: Lea and Febiger; 1989; p. 376.